AbbVie is engaged in new litigation over its blockbuster adalimumab (Humira). This week, the drug maker filed suit against Boehringer Ingelheim in a Delaware federal court, saying that BI will infringe on 74 of its patents for adalimumab in its development of a biosimilar product, BI 695501.
AbbVie is engaged in new litigation over its blockbuster adalimumab (Humira). This week, the drug maker filed suit against Boehringer Ingelheim (BI) in a Delaware federal court, saying that BI will infringe on 74 of its patents for adalimumab in its development of a biosimilar product, BI 695501.
AbbVie earned $16.08 billion on sales of Humira in 2016, and seeks to defend its sales against biosimilars in development by asserting its numerous patents for the drug. The patents at issue in this case vastly outnumber those litigated in a previous suit against Amgen over its own biosimilar; in that case, AbbVie asserted only 10.
“While AbbVie has spent vast resources over decades developing Humira, Boehringer seeks to copy AbbVie’s work and ignore AbbVie’s patents,” the drug maker said in its complaint. “But while the Biosimilar Price Competition and Innovation Act (BPCIA) gives Boehringer an abbreviated regulatory pathway for its biosimilar version of Humira, it does not give Boehringer license to infringe AbbVie’s patents.”
The complaint indicates that AbbVie will assert 8 of those 74 patents in its initial wave of litigation, and will undertake a second wave when BI provides 180-day notice of commercial marketing, as BI did not consent to AbbVie’s proposal of a single stage of litigation for all 74 patents.
The patents that AbbVie has chosen to assert in this litigation include composition, methods of treatment, methods of administration, use of anti-tumor necrosis factor antibodies, and methods of production, among others. Among the patents on AbbVie’s list is the so-called “‘135 patent” for a method of treating rheumatoid arthritis. Five claims of that patent were struck down by the US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) after a challenge from BI. The same claims were also invalidated by the PTAB in a previous inter partes review proceeding concerning Coherus BioScience’s CHS-1420.
Last week, BI announced that it had enrolled its first patient in a study to demonstrate interchangeability of its BI 695501 molecule with Humira. The results of the study—which will compare pharmacokinetics and clinical outcomes in 240 patients with moderate to severe chronic plaque psoriasis, and include safety, efficacy, and immunogenicity data—are expected in the second half of 2019.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.